N-[4-(Carboxy)benzyl]-N,N'-bis[(2-triphenylmethyl-thio)ethyl]glycinamide N-hydroxysuccinimide ester | 167215-80-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N-[4-(Carboxy)benzyl]-N,N'-bis[(2-triphenylmethyl-thio)ethyl]glycinamide N-hydroxysuccinimide ester
• 英文别名: (2,5-Dioxopyrrolidin-1-yl) 4-[[[2-oxo-2-(2-tritylsulfanylethylamino)ethyl]-(2-tritylsulfanylethyl)amino]methyl]benzoate；(2,5-dioxopyrrolidin-1-yl) 4-[[[2-oxo-2-(2-tritylsulfanylethylamino)ethyl]-(2-tritylsulfanylethyl)amino]methyl]benzoate
• CAS: 167215-80-7
• 化学式: C₅₆H₅₁N₃O₅S₂
• 分子量: 910.17
• InChiKey: FHMHVRRBASLYDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.7
• 重原子数：
  66
• 可旋转键数：
  21
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  147
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-[4-(Carboxy)benzyl]-N,N'-bis[(2-triphenylmethyl-thio)ethyl]glycinamide N-hydroxysuccinimide ester 、 在 TEA 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以53%的产率得到2-[(5S,11S,14R)-11-(3-carbamimidamidopropyl)-12-methyl-4,7,10,13,16-pentaoxo-19-[6-[[4-[[[2-oxo-2-(2-tritylsulfanylethylamino)ethyl]-(2-tritylsulfanylethyl)amino]methyl]benzoyl]amino]hexanoylamino]-14-propan-2-yl-3,6,9,12,15-pentazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid
  参考文献：
  名称：

  Tc-99m-labeled fibrinogen receptor antagonists: design and synthesis of cyclic RGD peptides for the detection of thrombi

  摘要：

  Tc-99m labeled derivatives of N-Me-Arg-Gly-Asp containing cyclic peptide GP IIb/IIIa receptor antagonists are potential radiopharmaceuticals for the diagnosis of thrombosis. The design and synthesis of these peptides are described. These compounds are incorporated in rapidly growing thrombi under both arterial and venous conditions in canine models. Thrombi are clearly visible in images acquired at 50 min. Copyright (C) 1996 The DuPont Merck Pharmaceutical Company.

  DOI：

  10.1016/0960-894x(96)00282-x
• 作为产物：
  描述：

  苯甲酸,4-[[(甲磺酰)氧代]甲基]-,甲基酯 在 sodium hydroxide 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 1,4-二氧六环 、 1,2-二氯乙烷 为溶剂， 生成 N-[4-(Carboxy)benzyl]-N,N'-bis[(2-triphenylmethyl-thio)ethyl]glycinamide N-hydroxysuccinimide ester
  参考文献：
  名称：

  Tc-99m-labeled fibrinogen receptor antagonists: design and synthesis of cyclic RGD peptides for the detection of thrombi

  摘要：

  Tc-99m labeled derivatives of N-Me-Arg-Gly-Asp containing cyclic peptide GP IIb/IIIa receptor antagonists are potential radiopharmaceuticals for the diagnosis of thrombosis. The design and synthesis of these peptides are described. These compounds are incorporated in rapidly growing thrombi under both arterial and venous conditions in canine models. Thrombi are clearly visible in images acquired at 50 min. Copyright (C) 1996 The DuPont Merck Pharmaceutical Company.

  DOI：

  10.1016/0960-894x(96)00282-x

文献信息

• Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
  申请人：——

  公开号：US20030003049A1

  公开（公告）日：2003-01-02

  The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.

  本发明提供了包括放射标记的LTB4结合剂和放射标记的灌注成像剂的新型诊断组合物，包括这种组合物的诊断试剂盒，以及在哺乳动物中进行同时成像的方法，包括给予放射标记的LTB4结合剂和放射标记的灌注成像剂，并同时检测结合在LTB4受体上的放射标记的LTB4结合剂和放射标记的灌注成像剂。
• Radiopharmaceuticals for imaging infection and inflammation
  申请人：——

  公开号：US20030124053A1

  公开（公告）日：2003-07-03

  The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备这些放射性药物的试剂和工具包，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位聚集的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1293214A3

  公开（公告）日：2003-03-26

  The present invention provides novel radiopharmaceutials useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备放射性药物的试剂和试剂盒，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位积聚的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
  申请人：Dupont Pharmaceuticals Company

  公开号：EP0995761A2

  公开（公告）日：2000-04-26

  This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to the methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.

  本发明提供了新型放射性药物，它们是含有碳环或杂环环系统的放射性标记环状化合物，可作为血小板糖蛋白 IIb/IIIa 复合物的拮抗剂；提供了将所述放射性药物用作诊断动脉和静脉血栓的成像剂的方法；提供了制备所述放射性药物的新型试剂；以及提供了包含所述试剂的试剂盒。
• RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS
  申请人：Dupont Pharmaceuticals Company

  公开号：EP0692982B1

  公开（公告）日：2000-07-05